Genetics of Schizophrenia

1. SCHIZOPHRENIA - GENETICS
PRESENTER - Dr. Sriram.R, 2nd year MD PG
CHAIRPERSON – Dr. Thenmozhi, AP

5. CONTENTS
• Abbreviations used
• Why study genetics of schizophrenia?
• Genetic terms used in SCZ
• Sub-groups of genetics in SCZ
• Family studies
• Twin studies
• Adoption studies
• Linkage studies
• Mode of inheritance
• Association studies and GWAS
• Chromosomal aberrations and CNVs
• Pleiotropy and overlap with BPAD/Autism
• Future directions

6. ABBREVIATIONS USED
• SCZ – Schizophrenia
• MZ- monozygotic
• DZ- dizygotic
• GWAS- Genome-wide Association Studies
• LD- Linkage Disequilibrium
• ISC- International Schizophrenia Consortium
• MGS- Molecular Genetics of Schizophrenia
• SGENE- Schizophrenia Genetics Consortium

7. Why study genetics of
schizophrenia?
• Overall, psychiatric diseases are
– First-rank public health problems
– Cause enormous morbidity, mortality and personal/societal cost
– Mostly idiopathic
– Despite considerable research, little known for certain about the
disease etiology
• Genetic knowledge of SCZ
– Can give a definite biological basis for distinguishing affected from
non-affected (Sullivan 2010)
– Can guide for newer treatments

8. GENETIC TERMS USED IN SCZ
• Concordance: the probability that a pair of individuals will both have a
certain characteristic, given that one of the pair has the characteristic. For
example, twins are concordant when both have or both lack a given trait.
(Lewontin,1982)
• Heritability: proportion of the variance of a phenotype (disease,trait) that
is due to genes, estimated from risks to twins and other relatives
• Mendelian disease: caused by a (usually rare) change(mutation) in DNA
sequence on one(dominant) or both(recessive) of an individual’s pair of
chromosomes
• Complex disease: caused by an interaction of multiple genetic and/or
environmental factors
• Allele: A variant of the similar DNA sequence located at a given locus is
called an allele.
• Haplotype: collection of specific alleles in a cluster of tightly-linked genes
on a chromosome that are likely to be inherited together

9. • Locus: a locus (plural loci) is the specific location of a gene, DNA
sequence, or position on a chromosome. Each chromosome carries many
genes; humans' estimated 'haploid' protein coding genes are 20,000-
25,000, on the 23 different chromosomes.
– Eg. The chromosomal locus of a gene might be written "6p21.3".
Because "21" refers to "region 2, band 1" this is read as "two one", not
as "twenty-one". So the entire locus is "six P two one point three"

10. • Genetic map: The ordered list of loci known for a particular genome is called
a genetic map.
• Gene mapping: Gene mapping is the process of determining the locus for a
particular biological trait.
• Genetic linkage is the tendency of alleles that are located close together on
a chromosome to be inherited together during meiosis. Genes whose loci are
nearer to each other are less likely to be separated onto
different chromatids during chromosomal crossover, and are therefore said to
be genetically linked. In other words, the nearer two genes are on a
chromosome, the lower is the chance of a swap occurring between them, and
the more likely they are to be inherited together.
• Linkage disequilibrium(LD): non-random association of alleles at two or
more loci that descend from single, ancestral chromosomes (Reich, 2001)
– A variant that is highly correlated with a truly causal variant will show a
similar statistical association to phenotype.
– If the LD is widespread, many fewer markers will need to be assayed
(Psychiatric GWAS consortium coordinating committee 2009)

11. • Mutation is a permanent change of the nucleotide sequence of the genome of
an organism, virus, or extrachromosomal DNA or other genetic elements
• SNP pronounced “snip”( Single nucleotide polymorphism)
– DNA sequence variation occurring commonly within a population (e.g.
1%) in which a single nucleotide — A, T, C or G — in the genome (or other
shared sequence) differs between members of a biological species or
paired chromosomes
– Common SNPs: ≥5% frequency ~10million in the genome- targets of the
GWAS
– Rare SNPs: <1% frequency

12. • Copy-number variations (CNVs)—a form of structural variation—are alterations of the
DNA of a genome that results in the cell having an abnormal or, for certain genes, a
normal variation in the number of copies of one or more sections of the DNA.
– CNVs correspond to relatively large regions of the genome that have been deleted
(fewer than the normal number) or duplicated (more than the normal number) on
certain chromosomes.
– For example, the chromosome that normally has sections in order as A-B-C-
D might instead have sections A-B-C-C-D (a duplication of "C") or A-B-D (a deletion
of "C").
• This variation accounts for roughly 13% of human genomic DNA and each variation may
range from about one kilobase (1,000 nucleotide bases) to several megabases in size
(Pawel et al, 2010)

13. • Genome-wide association study (GWA study, or GWAS), also known as whole
genome association study (WGA study, or WGAS) or common-variant
association study (CVAS), is an examination of many common genetic
variants in different individuals to see if any variant is associated with a trait.
– GWAS typically focus on associations between single-nucleotide
polymorphisms (SNPs) and traits like major diseases.
– compare the DNA of two groups of participants: people with the disease
(cases) and similar people without (controls). Each person gives a sample
of DNA, from which millions of genetic variants are read using SNP arrays.
– If one type of the variant (one allele) is more frequent in people with the
disease, the SNP is said to be "associated" with the disease.
• A polygene, multiple factor, multiple gene inheritance, or quantitative
gene is a group of non-allelic genes that together influence a phenotypic trait.
The precise loci or identities of the non-allelic genes are often unknown to
biologists.

14. • The common disease-common variant (often abbreviated CD-CV)
hypothesis predicts that common disease-causing alleles, or variants, will
be found in all human populations which manifest a given disease.
– Common variants (not necessarily disease-causing) are known to exist
in coding and regulatory sequences of genes.
– According to the CD-CV hypothesis, some of those variants lead to
susceptibility to complex polygenic diseases.
– Each variant at each gene influencing a complex disease will have a
small additive or multiplicative effect on the disease phenotype
• Pleiotropy occurs when one gene influences multiple, seemingly
unrelated phenotypic traits, an example being phenylketonuria, which is a
human disease that affects multiple systems but is caused by one gene
defect.

15. SUB-GROUPS OF GENETICS
IN SCZ
• Biochemical genetics: biochemical reactions by which genetic
determinants are replicated and produce their effects
• Developmental genetics: how the expression of normal genes controls
growth and developmental processes
• Molecular genetics: structure and functioning of genes at molecular level.
• Cytogenetics: chromosomes
• Population genetics: mathematical properties of genetic transmission in
families and populations- evolutionary genetics, genetic demography,
quantitative genetics, genetic epidemiology
• Quantitative genetics: goal is to partition the observed variation of
phenotypes into genetic and environmental components
• Genetic epidemiology: understanding the causes, distribution and control
of disease in groups of relatives and the multifactorial causes of disease in
populations

16. GENETIC BASIS OF SCHIZOPHRENIA

17. FAMILY STUDIES
• Study of families of probands to see if the relatives of the probands
have increased risk of developing the disease
• Ernst Rudin(1916): first systematic family study
• Other prominent researchers: Edith Zerbin-Rudin, Irving I.
Gottesman, Franz Kallmann, Manfred Bleuler
• Data showed the familial basis of schizophrenia with increased risk
of developing schizophrenia in the relatives of schizophrenic
patients
• Bezugsziffer: an age-adjusted size of the sample which takes into
account the fact that younger persons have not passed through the
full period of risk- traditionally 15-39yrs
• Average lifetime prevalence risk of 10% in siblings and children

18. MORBIDITY RISK FOR SCHIZOPHRENIA IN
RELATIVES OF SCHIZOPHRENIC PROBANDS :
GOTTESMANN AND SHIELDS

19. • Lower risk among parents explained by the
reduced reproductive fitness associated with
schizophrenia and the possibility of de novo
mutations causing the illness in the offspring*
• Earlier studies questioned on the
methodological grounds: no control groups,
diagnoses not made blind, no structured
interviews or operationalized diagnostic
criteria used

21. • No major difference in the findings of newer studies
as compared to that of older ones
• Significant difference for parents(5.6% in older ones
vs. 2.3% in newer) could be due to application of
more stringent diagnostic criteria*
• Confirmed the higher risk of SCZ in the relatives of
the probands but did not delineate the role of shared
genetic or environmental factors in this difference

22. Twin studies
Share the same genes and
the same environment
However one is usually
born bigger than the
other
Share as many genes as
siblings but share the
same environment
However they
might be
treated
differently
TWIN STUDIES

23. • Compare the concordance rates in Monozygotic(MZ)
and Dizygotic(DZ) twins
• MZ twins share all their genes while DZ twins share
on average 50% of their genes
• Assuming twins share common environment,
– higher concordance in MZ twins than in DZ implies
genetic origin
– Concordance of less than 100% in MZ twins
indicate the role of environment

24. •Gottesman and Shields reviewed the results of 5 twin
studies looking for concordance rates for schizophrenia.
These studies looked at 210 MZ twins and 319 DZ twins.
It was found that in MZ twins there was a concordance
rate of 35-58% compared with dizygotic (DZ) twin rates
that ranged from 9-26%.
They also found a concordance rate in MZ twins of 75-
91% when the sample was restricted to the most severe
form of schizophrenia.
•Cardno (2002) – showed concordance rate of 26.5% MZ
and 0% for DZ

25. • Pairwise concordance: simply the number of concordant pairs
divided by the total number of pairs
• Probandwise concordance: each of the concordant twin is counted
i.e. the pair is counted twice and is ascertained by
– number of affected co-twins/ the number of probands
– Gives the risk for the twin of a person suffering from SCZ to
become ill him/her-self
– Preferred by geneticists- technically more correct and directly
comparable to population risks reported in family studies
• Probandwise concordance in MZ twins: 25%(n=8)(Essen-
Moller,1970) 78%(n=245)(Kallmann,1946)
• Probandwise concordance in same-sex DZ twins:
0%(n=50)(Cardno,1998)- 28% (n=25)(Franzek and Beckmann,1998)
• Heritability: 41%- 90%- very similar estimates with both the
methodologically superior and inferior studies (Sullivan)

26. • Meta-analyses of heritability:
– Sullivan- 81% (Sullivan, 2007)
– Cardno and Gottesmann- 88% (Cardno, 2000)
• High agreement between studies conducted in different countries over
nearly a century
• Calculation based on assumptions:
– Polygenic multifactorial threshold model
– Similar risk of SCZ in twins as in general population
– DZ and MZ twins share similar environment
• Identical twins reared apart: theoretically nullifies the effects of shared
environment (Gottesmann and Shields) = 64%
• Possible explanations for the discordance in MZ twins:
– Affected co-twin suffers from an environmentally determined form of
the disorder
– Both twins inherited the same genetic liability but only expressed in
the affected twin
• Explained by the study of risk in the offspring of discordant SCZ twins

27. • First study
– 11 SCZ twins, 47 offspring with 6 developing SCZ = 16.8%
– 6 unaffected twins, 24 offspring with 4 developing SCZ = 17.4%
• Second study
– 28 offspring of SCZ twins with 3 developing SCZ = 10.7%
– 45 offspring of unaffected twins with 1 developing SCZ = 2.2%
• Combined:
– risk among offspring of SCZ twins, 9/75 = 12%
– Risk among offspring of unaffected, 5/69 = 7.2%
• (P=0.38) No significant difference, similar morbidity risk consistent
with unexpressed risk
(Kirov , 2009)

28. ADOPTION STUDIES
• Allow dissection of genetic from environmental contributions in ways that
twin studies cannot.
• If there is a genetic component to the disorder, the similarity between the
adopted children and their biological parents should be higher than the
similarity between adopted children and their adoptive parents.
• Adoption itself does not increase the risk for developing SCZ among
adopted children.
• Leonard Heston, 1966:
– 47 adopted children of mothers suffering from SCZ and other
psychoses, separated within 3days of birth- by age 36, 5 developed
SCZ (10.6%)
– None out of 50 children in the control group had SCZ
• David Rosenthal, 1971:
– Studied 5500 adoptees 14/52 (26.9%) children of SCZ parents had SCZ-
spectrum disorder
– 12/67 control (17.9%) had illness of similar spectrum

29. • M. W. Higgins, 1976:
– 50 children of SCZ mothers
– 4/23 (17.9%) children reared by SCZ mothers had SCZ
– Of 25 children adopted away, 4(16%) SCZ
• Seymour S. Kety et al, 1994
– 14/279 (5%) biological relatives of SCZ adoptees had chronic SCZ
– None out of 111 adoptive relatives had SCZ
– 1/351 (0.3%) biological + adoptive relatives of unaffected adoptees had SCZ
• Pekka Tienari, 2000:
– 164 adopted children of mothers suffering from SCZ
• SCZ- 11(6.7%)
• Schizoaffective- 1(0.6%)
• Schizotypal personality disorder- 4(2.4%)
• Overall narrow spectrum SCZ disorder- 10.4%
– 197 control adoptees
• SCZ - 4(2%)

30. • CONCLUSION:
– Overall at least 10% risk of developing SCZ and
other narrow-spectrum SCZ disorders in adopted
away children of SCZ parents
– Risk similar to that in offspring in family studies ->
genetic basis of transmission of SCZ

31. LINKAGE STUDIES
• Use of large number of small families containing
individuals who are definitely affected rather than
large, multigenerational pedigrees
• At least 27 whole genome studies that analyzed
between 1 to 294 pedigree containing between 32 to
669 patients of SCZ
• J. A. Badner and E.S. Gershon - susceptibility genes
on chromosomes -› 8p, 13q and 22q
• Cathryn M. Lewis et al ->
– Strong evidence for 2q
– 1q, 3p, 5p, 6p, 8p, 11q, 14q, 20q and 22q

33. • Meta-analysis by Sullivan- › Only 42%, 35%, 14%, 6%
and 3% of all known genes were implicated by zero,
one, two, three and four linkage studies
• It is an imprecise tool
• Possible explanations for the varied linkage findings:
– Different genes operate in different populations
– SCZ is caused by the effect of many genes of small
effect, so studies had no power to detect the loci

34. MODE OF INHERITANCE
• Hypotheses regarding genetic background of common diseases
including SCZ:
– Common disease/common variant hypothesis:
• Common diseases caused by common variants
• Joint action of several common genetic variants, each has a small
effect on disease susceptibility, together with environmental factors
• Could range into thousands
– Multiple rare variants in different genes, which have low
population frequencies, operate in different individuals:
• lack of families with clear cut Mendelian Inheritance
• Inability of linkage studies to find any causative mutation
• Mathematical modeling is inconsistent with single gene of large effect
• A small number of cases of SCZ could be due to rare chromosomal
aberrations with high penetrance

35. ASSOCIATION STUDIES
• Implicate a specific gene by identifying a correlation between a disease and alleles
at a specific genetic locus
• Compares the frequency of marker genotypes in cases with an appropriate control
group
• SNPs are the most common source of genetic measurement in association studies

36. • Dystrobrevin-binding protein1(DTNBP1)/dysbindin
– First reported by Richard E. Straub and colleagues in 2002
– On chromosome 6p22.3
– Konrad Talbot(2004)- presynaptic dystrobrevin-independent fraction
reduced in SCZ brain within certain glutamatergic neurons in the
hippocampus-> Associated with increased expression of vesicular
glutamate transporter type 1 ->Alteration in presynaptic glutamate
function
– The expression of dysbindin proteins is decreased in the brains of
schizophrenia patients, and neurons in mice carrying a deletion in
the dysbindin gene have fewer dendritic spines (Jie-Min Jia et al,
2014)
– Significant associations found between SCZ and several SNPs and
multimarker haplotypes spanning DTNBP1
– Support from other large studies as well - at least 10 studies
– Some studies showing no association
– Inconsistencies indicative of presence of multiple susceptibility and
protective alleles

38. • Neuregulin 1(NRG1)
– Encodes multiple proteins with diverse range of functions in the
brain
• Cell-cell signaling , ErbB receptor interactions ,Axon guidance,
Synaptogenesis, Glial differentiation, Myelination, Neurotransmission
• Located on 8p21-22
– Plays a role in synaptic plasticity. It has been shown that a loss
of Neuregulin 1 within cortical projection neurons results in
increased inhibitory connections and reduced synaptic plasticity
– First implicated from linkage study in Icelandic sample
– Further positive findings supported by studies from UK, Irish,
Chinese, Bulgarian and South African samples
– Only 3 other studies replicating the specific haplotype ->
differences in linkage disequilibrium

39. • Other genes:
– Catechol-O-Methyltransferase (COMT)
– Proline Dehydrogenase (PRODH)
– Regulator of G-protein signaling4 (RGS4)
– D-Amino-acid oxidase (DAO)
– D-Amino-acid oxidase activator (DAOA)
– G72/G30
– CAPON
– AKT1

40. GWAS
• Common variant SNPs:
– minor allele frequency of SNPs>0.05
– The effect sizes of the associations likely to be very small, so
hundreds and even thousands of genes might contribute small
effects to the pathogenesis of SCZ
• RELN gene:
– › Relin protein- a serine protease important in corticogenesis
(Hong et al, 2000)
– › Implicated in neurotransmitter-related GSK3β signaling and
regulation of NMDA receptor activation (Herz, 2006)
– › Polymorphism in RELN associated with neurocognitive
endophenotypes of SCZ (working memory and executive
functioning) (Wedenoja, 2008)

41. • Genome-pooling based study
– rs11064768 in intron 1 of CCDC60 on 12q24.23
– rs11782269 on 8p23.1
– RBP1 on 3q23- implicated in SCZ pathogenesis
– Not replicated in other studies and no genome-wide significance
– Suggestive of neurodevelopmental hypothesis of SCZ (Keshavan et al
2004)
• Zinc finger protein 804A(ZNF804A)
– › Located on 2q32.1
– › Putative transcription factor
– › Shown to be associated with disturbed connectivity between the
dorsolateral prefrontal cortex (DLPFC) & the hippocampus; between rt.
and lt. hemisphere (Esslinger et al 2009)
– › Strong association with SCZ and BPAD
– › Supported by replication in other large studies as well

42. • Major histocompatibility complex(MHC):
– Significant association shown by the meta- analysis of the three major GWAS (ISC, MGS,
and SGENE) at the MHC region on chromosome 6p
– Genes in the MHC region have different functions, immune function predominate
– Histones regulate DNA transcription by chromatin modification and have role as
antimicrobial agent
– Genetic variation in histones might underlie differential placental susceptibility to
infection -> susceptibility to SCZ (Gejman et al 2010)
– Danish study registry shows increased risk of autoimmune diseases for schizophrenics
and a history of any autoimmune disorder(n=29) associated with 45% increase in the
risk for SCZ (Eaton et al, 2006)

43. • Neurogranin(NRGN):
– On chromosome 11
– Encodes a postsynaptic protein kinase substrate that binds calmodulin,
mediating NMDA receptor signaling
– important for learning & memory, relevant to proposed glutamate
pathophysiology of SCZ (Wang et al, 2008)
• Transcription factor 4 (TCF4):
– › On chromosome 18
– › Neuronal transcriptional factor essential for brain development, esp.
neurogenesis
– › Mutations cause Pitt-Hopkins syndrome, a neuro-developmental
disorder

44. • International Schizophrenia Consortium ( ISC) conclusion:
– › Thousands of common polygenic variants with very small individual effects
explain about 1/3rd of the total variation in genetic liability to SCZ (Purcell et
al, 2009)
– › The remaining heritability is still missing even after the well powered GWAS
studies

45. Chromosomal aberrations
and CNVs
• CNVs:
– › are stretches of genomic deletions & duplications ranging
from 1kb to several Mb
– › Likely to have larger phenotypic effects than SNPs
– › Only rare(<1%) and large(>100kb) CNVs have been
implicated in SCZ
• Chromosome 22q11.21 deletion syndrome
• Velocardiofacial syndrome
• Increased risk for SCZ , >30% carriers develop
psychosis,80% of which as SCZ
• Largest known individual risk factor for SCZ second only
to having an identical twin with SCZ

46. • 2p16.3 Neurexin1 (NRXN1) deletion:
– NRXN presynaptic cell adhesion molecule
– Interacts with post synaptic cell adhesion molecules including neuroligins
– Believed to play important role in release of neurotransmitter from
presynaptic vesicles and together with neuroligins involved in synapse
formation and use-dependent validation of neural circuits
– Partial overlapping observed in mentally retarded and autistic patients
• Disrupted In Schizophrenia (DISC1):
– Balanced chromosomal translocation in(1,11) (q42;q14.3)
– Disrupt two genes in chromosome1 : DISC1 & DISC2
– Strong evidence of linkage to- SCZ, BPAD and recurrent depression
– May contribute to SCZ by affecting neuronal functions dependent on intact
cytoskeletal regulation such as
• Neuronal migration
• Neurite architecture
• Intracellular transport

47. OTHER CNVs:
• 15q13.1 duplication
– Duplicated interval in the proband contains 3 genes of
which APBA2 appears most likely
– APBA2 interacts with NRXN1
• 1q21.1 deletion
• 15q13.2 deletion
• 15q13.3 deletion
– Also found in pts. With mental retardation and
seizures
• 16p11.2 duplication

48. Pleiotropy and overlap
with BPAD/Autism
• Many of the genes positive for SCZ also positive for
BPAD and vice versa
– With BPAD
• DISC1
• NRG1
• RELN
• ANK3
– With autism - Neurexin 1
• Could have implication for diagnostis of SCZ and also
lead to newer etiological and pathophysiological
explanations of the psychiatric disorders

49. Ayalew et al, 2012

50. FUTURE DIRECTIONS
• Standardization of the phenotypes:
– › Syndromal diagnosis
– › Broad variations
• The effect size associated with common variant is very low
and the number of total susceptibility variants may be in the
order of thousands requiring upto 100,000 cases and controls
for replicating the findings
– › To achieve such sample sizes with detailed and consistent
phenotype measurement is a challenge
• Combining all diseases of a spectrum e.g. psychosis, broadly
can give large sample size and also detect genes that overlap
• Narrow the phenotype ->more homogenous sub-group ->
smaller number of genes of greater effect sizes

51. • Use of endophenotypes (Gould 2006):
– Disease associated phenotypes that are heritable, state independent,
cosegregate with families and also found in unaffected family
members
• E.g. Abnormal eye movement while tracking a moving object in screen
• Neurocognitive deficits- COMT & RELN
• Structural imaging phenotypes
– Creates phenotypically more homogenous group
• Consideration of the effect of environmental factors such as maternal
infections, and drug use
• Consideration of epigenetic mechanisms
• Use of high-throughput whole-genome sequencing: Has potential to
detect virtually all SNPs, CNVs and epigenetic modifications*, Will provide
comprehensive information of an individual at the DNA level. Cost is a
concern.
• More accurate study of the target organ in SCZ research (brain) can lead to
more objective and reliable associations with the genetic variants

54. REFERENCES
• Sullivan PF. The psychiatric GWAS consortium: Big science comes to psychiatry. Neuron
2010;68(2): 182-186
• Psychiatric GWAS Consortium Coordinating Committee. Genomewide association studies:
history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009;166:540-556
• Kirov G, Owen MJ: Genetics of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors.Kaplan
and Saddock’s Comprehensive Textbook of Psychiatry.9th edition. Lippincot Williams and
Wilkins; Philadelphia;2009.p 1462-1475
• Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait. Evidence from a meta-
analysis of twin studies. Arch Gen Psychiatry. 2007;60:1187. Cited in: Kirov G, Owen MJ:
Genetics of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors.Kaplan and Saddock’s
Comprehensive Textbook of Psychiatry.9th edition. Lippincot Williams and Wilkins;
Philadelphia;2009.p 1462-1475.
• Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow- and-arrow concordances
to star war MMx and functional genomics. Am J Med Genet. 2000;97:12. Cited in: Kirov G,
Owen MJ: Genetics of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors.Kaplan and
Saddock’s Comprehensive Textbook of Psychiatry.9th edition. Lippincot Williams and Wilkins;
Philadelphia;2009.p 1462-1475.
• Pawel Stankiewicz, James R. Lupski (2010). "Structural Variation in the Human Genome and
its Role in Disease". Annual Review of Medicine 61: 437–455.
• Stearns, F. W. (2010). One Hundred Years of Pleiotropy: A Retrospective. Genetics 186(3):767-
773. http://www.genetics.org/content/186/3/767.abstract

55. • Hong SE, Shugart YY, Huang DT, et al. Autosomal recessive lissencephaly with cerebellar
hypoplasia is associated with human RELN mutations. Nat Genet. 2000;26:93-96. Cited in:
Tiwari AK, Zai CC, Muller DJ, Kennedy JL. Genetics in schizophrenia: where are we and what
next? Dialogues in clinical neuroscience 2010;3(12):289-303.
• Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci.
2006;7:850-859. Cited in: Tiwari AK, Zai CC, Muller DJ, Kennedy JL. Genetics in schizophrenia:
where are we and what next? Dialogues in clinical neuroscience 2010;3(12):289-303.
• Wedenoja J, Loukola A, Tuulio-Henriksson A, et al. Replication of link-age on chromosome
7q22 and association of the regional Reelin gene with working memory in schizophrenia
families. Mol Psychiatry. 2008;13:673-684. Cited in: Tiwari AK, Zai CC, Muller DJ, Kennedy JL.
Genetics in schizophrenia: where are we and what next? Dialogues in clinical neuroscience
2010;3(12):289-303.
• Keshavan MS, Kennedy JL, Murray R, eds. Neurodevelopment and Schizophrenia. Cambridge,
UK: Cambridge University Press; 2004. Cited in: Tiwari AK, Zai CC, Muller DJ, Kennedy JL.
Genetics in schizophrenia: where are we and what next? Dialogues in clinical neuroscience
2010;3(12):289-303
• Agarwal A, Zhang M, Trembak-Duff I, Unterbarnscheidt T, Radyushkin K, Dibaj P et al. (2014).
"Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic
plasticity". Cell Reports 8 (4): 1130–45.
• M Ayalew et al., Convergent functional genomics of schizophrenia: from comprehensive
understanding to genetic risk prediction, Molecular Psychiatry, 2012

56. • Esslinger C, Walter H, Kirsch P, et al. Neural mechanisms of a genome-wide
supported psychosis variant. Science. 2009;324:605. Cited in : Tiwari AK, Zai CC,
Muller DJ, Kennedy JL. Genetics in schizophrenia: where are we and what next?
Dialogues in clinical neuroscience 2010;3(12):289-303
• Gejman VP, Sanders AR, Duan J. the role of genetics in the etiology of
Schizophrenia. Psychiatr Clin North Am. 2010; 33(1): 35–66
• Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune
diseases: linkage of Danish national registers. Am J Psychiatry 2006;163:521. Cited
in: Gejman VP, Sanders AR, Duan J. the role of genetics in the etiology of
Schizophrenia. Psychiatr Clin North Am. 2010; 33(1): 35–66
• Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to
risk of schizophrenia and bipolar disorder. Nature 2009;460:748
• Gould TD, Gottesman, II. Psychiatric endophenotypes and the development of
valid animal models. Genes Brain Behav. 2006;5:113- 119. cited in : Tiwari AK, Zai
CC, Muller DJ, Kennedy JL. Genetics in schizophrenia: where we are and what next.
Dialogues in clinical neuroscience 2010;3(12): 289-303.
• Stahl SM, editor. Stahl’s Essential Psychopharmacology. 3rd edition. Cambridge
University Press; New Delhi;2008. p. 318.

57. THANK YOU